1. Lumoxiti is an injection for the treatment of adult patients with relapse or refractory hairy cell leukemia, a rare slow-growing cancer in the blood.
2. Cassipa is a buprenorphine and naloxone sublingual film for the treatment of opioid dependence. The FDA approval provides a new dosage strength of the film.
3. Amneal Pharmaceuticals received approval for its generic version of chlorpromazine hydrochloride tablets to treat psychotic disorders or prevent and treat nausea and vomiting.
More articles on supply chain:
AT&T, Merck pilot drones to deliver medical supplies to Puerto Rico
FDA designates bloodless AI test a ‘breakthrough device’
AHRMM names Dee Donatelli chair-elect, announces new board members
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.